Cancer glossary
HE4 and the ROMA index: assessing ovarian cancer risk with a blood test
HE4 is an ovarian cancer tumor marker; ROMA is an index calculated from HE4, CA-125 and menopausal status. What they show, why they matter for an ovarian mass and what not to expect.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026
In short
HE4 (human epididymis protein 4) is a tumor marker that is often raised in ovarian cancer. ROMA is a calculated index: it combines HE4, CA-125 and menopausal status and shows the probability that an ovarian mass is malignant.
How it appears in your report
- ‘HE4 52 pmol/L’.
- ‘ROMA 8.1% — low risk’ / ‘ROMA 41% — high risk’.
- Thresholds differ before and after menopause — the lab lists them on the form.
What it means
According to the US National Cancer Institute, HE4 is used to plan treatment and follow ovarian cancer. The main practical role of HE4 and ROMA is before surgery: with an ovarian mass they help decide who needs surgery with a gynecologic oncologist and who can be watched or seen by a general gynecologist. After treatment, HE4 together with CA-125 helps watch for recurrence.
HE4 can rise with kidney disease, smoking and age — this is taken into account.
Does it affect treatment
It affects the route: a high ROMA is a reason to have surgery at a cancer center. The diagnosis itself is made only by pathology.
Questions to ask your doctor
- What is my ROMA risk, and what next — monitoring or surgery?
- Who will operate — a gynecologic oncologist?
- Do I need a BRCA test?
Sources
- Tumor Markers in Common Use — National Cancer Institute
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ) — National Cancer Institute
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
